jiajia321
2021-05-11
Gg
Novavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>Novavax因延迟向监管机构提交COVID-19疫苗而股价走低</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
5
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":199418654,"tweetId":"199418654","gmtCreate":1620725817678,"gmtModify":1634196817973,"author":{"id":3576228066699478,"idStr":"3576228066699478","authorId":3576228066699478,"authorIdStr":"3576228066699478","name":"jiajia321","avatar":"https://static.tigerbbs.com/b78078be18e2c45700ab0923b697b201","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Gg</p></body></html>","htmlText":"<html><head></head><body><p>Gg</p></body></html>","text":"Gg","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/199418654","repostId":1128439536,"repostType":4,"repost":{"id":"1128439536","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620721615,"share":"https://www.laohu8.com/m/news/1128439536?lang=zh_CN&edition=full","pubTime":"2021-05-11 16:26","market":"us","language":"en","title":"Novavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>Novavax因延迟向监管机构提交COVID-19疫苗而股价走低</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128439536","media":"Tiger Newspress","summary":"(May 11) Confirming the media reports, Novavx(NASDAQ:NVAX) has delayed its plans for regulatory subm","content":"<p>(May 11) Confirming the media reports, Novavx(NASDAQ:NVAX) has delayed its plans for regulatory submissions for the COVID-19 vaccine in the U.S. U.K.and European Medicines Agency (EMA).</p><p><blockquote>（5月11日）证实了媒体报道，Novavx（纳斯达克代码：NVAX）推迟了向美国、英国和欧洲药品管理局（EMA）提交新冠肺炎疫苗的监管申请的计划。</blockquote></p><p>The company now intends to file authorization for NVX-CoV2373 in Q3 2021. Novavax has beaten the consensus with its Q1 2021 financials, but the vaccine setback has hurt the shares which have lost nearly 13% in pre-market now.</p><p><blockquote>该公司现在打算在2021年第三季度提交NVX-CoV2373的授权。Novavax的2021年第一季度财务数据超出了市场普遍预期，但疫苗的挫折损害了其股价，目前盘前已下跌近13%。</blockquote></p><p>Novavax has completed the enrollment of the pivotal Phase 3 trials in the U.S. and Mexico, and the final analysis is expected to be reported in Q2 2021, the company said.</p><p><blockquote>该公司表示，Novavax已在美国和墨西哥完成关键3期试验的入组，最终分析预计将于2021年第二季度报告。</blockquote></p><p>The global manufacturing capacity for the vaccine has been revised up to 100M doses per month by the end of Q3 2021, and a capacity of 150M doses per month is expected by Q4 2021.</p><p><blockquote>到2021年第三季度末，该疫苗的全球生产能力已修订为每月1亿剂，预计到2021年第四季度，产能将达到每月1.5亿剂。</blockquote></p><p>Revenue has risen ~149x to ~$447M due to increased development work relating to NVX-CoV2373 for services performed under the agreements signed with the U.S. government and Coalition for Epidemic Preparedness Innovations.</p><p><blockquote>由于根据与美国政府和流行病防范创新联盟签署的协议提供的服务中与NVX-CoV2373相关的开发工作增加，收入增长了约149倍，达到约4.47亿美元。</blockquote></p><p>With R&D expenses rising ~34.9x from the previous quarter to $593M, the net loss in Q1 2021 has expanded ~8.6x from the previous year to $223M.</p><p><blockquote>随着研发费用较上一季度增长约34.9倍至5.93亿美元，Q1 2021年的净亏损较上年扩大约8.6倍至2.23亿美元。</blockquote></p><p>However, cash and equivalents have jumped to $2B compared to $806M in 2020-year end primarily due to $772M received from advance purchase agreements recognized as deferred revenue.</p><p><blockquote>然而，与2020年底的8.06亿美元相比，现金及等价物已跃升至20亿美元，这主要是由于从确认为递延收入的预购协议中收到的7.72亿美元。</blockquote></p><p>The previously announced timeline for the EUA (Emergency Use Authorization) submission was Q2 2021.</p><p><blockquote>此前宣布的EUA（紧急使用授权）提交时间表是Q2 2021。</blockquote></p><p><img src=\"https://static.tigerbbs.com/68316eaff6bc94d588de0dd64c00496b\" tg-width=\"786\" tg-height=\"494\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>Novavax因延迟向监管机构提交COVID-19疫苗而股价走低</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>Novavax因延迟向监管机构提交COVID-19疫苗而股价走低</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-05-11 16:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(May 11) Confirming the media reports, Novavx(NASDAQ:NVAX) has delayed its plans for regulatory submissions for the COVID-19 vaccine in the U.S. U.K.and European Medicines Agency (EMA).</p><p><blockquote>（5月11日）证实了媒体报道，Novavx（纳斯达克代码：NVAX）推迟了向美国、英国和欧洲药品管理局（EMA）提交新冠肺炎疫苗的监管申请的计划。</blockquote></p><p>The company now intends to file authorization for NVX-CoV2373 in Q3 2021. Novavax has beaten the consensus with its Q1 2021 financials, but the vaccine setback has hurt the shares which have lost nearly 13% in pre-market now.</p><p><blockquote>该公司现在打算在2021年第三季度提交NVX-CoV2373的授权。Novavax的2021年第一季度财务数据超出了市场普遍预期，但疫苗的挫折损害了其股价，目前盘前已下跌近13%。</blockquote></p><p>Novavax has completed the enrollment of the pivotal Phase 3 trials in the U.S. and Mexico, and the final analysis is expected to be reported in Q2 2021, the company said.</p><p><blockquote>该公司表示，Novavax已在美国和墨西哥完成关键3期试验的入组，最终分析预计将于2021年第二季度报告。</blockquote></p><p>The global manufacturing capacity for the vaccine has been revised up to 100M doses per month by the end of Q3 2021, and a capacity of 150M doses per month is expected by Q4 2021.</p><p><blockquote>到2021年第三季度末，该疫苗的全球生产能力已修订为每月1亿剂，预计到2021年第四季度，产能将达到每月1.5亿剂。</blockquote></p><p>Revenue has risen ~149x to ~$447M due to increased development work relating to NVX-CoV2373 for services performed under the agreements signed with the U.S. government and Coalition for Epidemic Preparedness Innovations.</p><p><blockquote>由于根据与美国政府和流行病防范创新联盟签署的协议提供的服务中与NVX-CoV2373相关的开发工作增加，收入增长了约149倍，达到约4.47亿美元。</blockquote></p><p>With R&D expenses rising ~34.9x from the previous quarter to $593M, the net loss in Q1 2021 has expanded ~8.6x from the previous year to $223M.</p><p><blockquote>随着研发费用较上一季度增长约34.9倍至5.93亿美元，Q1 2021年的净亏损较上年扩大约8.6倍至2.23亿美元。</blockquote></p><p>However, cash and equivalents have jumped to $2B compared to $806M in 2020-year end primarily due to $772M received from advance purchase agreements recognized as deferred revenue.</p><p><blockquote>然而，与2020年底的8.06亿美元相比，现金及等价物已跃升至20亿美元，这主要是由于从确认为递延收入的预购协议中收到的7.72亿美元。</blockquote></p><p>The previously announced timeline for the EUA (Emergency Use Authorization) submission was Q2 2021.</p><p><blockquote>此前宣布的EUA（紧急使用授权）提交时间表是Q2 2021。</blockquote></p><p><img src=\"https://static.tigerbbs.com/68316eaff6bc94d588de0dd64c00496b\" tg-width=\"786\" tg-height=\"494\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128439536","content_text":"(May 11) Confirming the media reports, Novavx(NASDAQ:NVAX) has delayed its plans for regulatory submissions for the COVID-19 vaccine in the U.S. U.K.and European Medicines Agency (EMA).The company now intends to file authorization for NVX-CoV2373 in Q3 2021. Novavax has beaten the consensus with its Q1 2021 financials, but the vaccine setback has hurt the shares which have lost nearly 13% in pre-market now.Novavax has completed the enrollment of the pivotal Phase 3 trials in the U.S. and Mexico, and the final analysis is expected to be reported in Q2 2021, the company said.The global manufacturing capacity for the vaccine has been revised up to 100M doses per month by the end of Q3 2021, and a capacity of 150M doses per month is expected by Q4 2021.Revenue has risen ~149x to ~$447M due to increased development work relating to NVX-CoV2373 for services performed under the agreements signed with the U.S. government and Coalition for Epidemic Preparedness Innovations.With R&D expenses rising ~34.9x from the previous quarter to $593M, the net loss in Q1 2021 has expanded ~8.6x from the previous year to $223M.However, cash and equivalents have jumped to $2B compared to $806M in 2020-year end primarily due to $772M received from advance purchase agreements recognized as deferred revenue.The previously announced timeline for the EUA (Emergency Use Authorization) submission was Q2 2021.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2174,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/199418654"}
精彩评论